Glycosaminoglycan News and Research

RSS

Glycosaminoglycan is a type of long, unbranched polysaccharide molecule. Glycosaminoglycans are major structural components of cartilage and are also found in the cornea of the eye.

Human microbiome trims mucosal glycans, influencing SARS-CoV-2 infection

An international team of researchers has conducted a study showing that differences in the human microbiome may influence the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.

19 Aug 2020

Common FDA-approved drug may be a powerful tool in fighting COVID-19

A common drug, already approved by the Food and Drug Administration, may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research.

15 Jul 2020

Severity of COVID-19 linked to heparanase activity and heparan sulfate levels

Researchers at Radboud University Medical Center in the Netherlands reported an increase of heparanase activity and heparan sulfate levels in the plasma of patients with coronavirus disease (COVID-19), which was also associated with the severity of the condition – suggesting, in turn, potential treatment utility of low molecular weight heparins. The paper is currently available on the medRxiv* preprint server.

16 Jun 2020

Heparin may stop SARS-CoV-2 infecting host cells

Researchers at the University of Sheffield have developed a new assay that can be used to assess the attachment of viruses to host cells and to test potential inhibitors of viral infection.

24 May 2020

Study reveals antiviral properties of glycosaminoglycans against SARS-CoV-2

Glycosaminoglycans can inhibit cell invasion by acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other coronaviruses, which supports the utilization of such therapeutics in the fight against coronavirus disease (COVID-19) – reports a new study available on the preprint server bioRxiv.

3 May 2020

Neurobiological pathophysiology of schizophrenia differs based on gender

The neurobiological pathophysiology of schizophrenia differs significantly between males and females, according to a new study.

4 Sep 2019

A metabolic intermediate in the uronic acid pathway impairs lung cancer metastasis

In a study published online in Nature on June 26, research teams led by Dr. YANG Weiwei at the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences and Dr. LI Guohui from the Dalian Institute of Chemical Physics of CAS reported a new function of uridine diphosphate glucose (UDP-glucose), a metabolic intermediate in the uronic acid pathway: It impairs lung cancer metastasis by accelerating SNAI1 mRNA decay.

27 Jun 2019

FACS-based CRISPR screening shows how Chlamydia bacterium invades host cells

Using FACS-based CRISPR screening, scientists have identified three candidate genes that may facilitate the invasion of Chlamydia trachomatis into host cells.

19 Jun 2019

KU researcher studies how estrogen may protect menisci between thighbone and shinbone

More than 30 million Americans suffer from osteoarthritis of the knee, according to the Centers for Disease Control and Prevention.

9 Jan 2019

Scientists explore whether seafood could be the source of next anti-cancer drug

Biomedical scientists at the University of Salford found that sugars from the common cockle were approximately as effective as some standard chemotherapy drugs at relative lower dosage.

17 Sep 2018

Novel, stem cell-based model mimics mechanisms of Alzheimer's disease

Scientists in Dresden, Germany, have been successful in mimicking mechanisms of Alzheimer's disease in a novel, stem cell-based model system that reproduces features of human brain tissue.

3 Jul 2018

High leisure-time physical activity improves cartilage health in postmenopausal women with knee OA

Higher leisure-time physical activity (LTPA) level promotes cartilage health in postmenopausal women with mild knee osteoarthritis (OA).

14 Mar 2017

Synthetic heart valve one step closer to reality

The quest for a synthetic heart valve that faithfully mimics the original is a step closer to its goal with the Rice University find that a natural polymer called hyaluronan, one of the chief components of skin and connective tissue, can serve as a versatile template for growing spongiosa, the middle tissue layer in the valve's leaflets.

12 May 2016

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients.

16 Mar 2016

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology.

21 Jan 2016

Janssen doses first patient in daratumumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that Janssen Biotech, Inc. has dosed the first patient in a clinical trial evaluating subcutaneous (SC) delivery of daratumumab with Halozyme's proprietary ENHANZE technology in multiple myeloma.

5 Nov 2015

Halozyme Therapeutics announces initiation of rivipansel Phase 1 clinical trial

Halozyme Therapeutics, Inc. today announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of a subcutaneous formulation of rivipansel, a compound discovered by GlycoMimetics, Inc. and being developed by Pfizer Inc., using Halozyme's ENHANZE formulation.

30 Oct 2015

TGen researchers join international scientists in discovering how malaria protein could some day help stop cancer

Researchers at the Translational Genomics Research Institute joined an international team of scientists in discovering how a protein from malaria could some day help stop cancer.

19 Oct 2015

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.

31 Jul 2015

Halozyme announces positive Phase 2 results of PEGPH20 drug for treating metastatic pancreatic cancer patients

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced interim findings from the ongoing phase 2 clinical study of its investigational new drug PEGPH20 for the potential treatment of patients with metastatic pancreatic cancer.

1 Jun 2015